PanGIA Biotech to Expand Multi-Cancer Early Detection Liquid Biopsy Study
PanGIA Biotech is preparing to launch new clinical studies in multi-cancer early detection using the PanGIA Liquid Biopsy Platform.
Read MorePosted by Andy Lundin | Jan 9, 2024 | Cancer, Research |
PanGIA Biotech is preparing to launch new clinical studies in multi-cancer early detection using the PanGIA Liquid Biopsy Platform.
Read MorePosted by Andy Lundin | Jan 9, 2024 | Diagnostic Technologies |
Picodya, the creator of a hybrid IVD solution for multiplexed POC testing, announced the deployment of its B-Matrix technology in NIH labs.
Read MorePosted by Andy Lundin | Jan 3, 2024 | Prostate |
ArteraAI says the CMS decided on the payment rate for the ArteraAI Prostate Test, a clinical diagnostic laboratory test for prostate cancer.
Read MorePosted by Chris Wolski | Dec 26, 2023 | Prostate |
UCLA Researchers have received a five-year, $3 million grant to develop AI that can detect and predict aggressive prostate cancer.
Read MorePosted by Andy Lundin | Dec 13, 2023 | Lung Cancer |
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read More